Spago Nanomedical appoints Paul Hargreaves as Chief Development Officer
Spago Nanomedical AB (publ) announced today that Paul Hargreaves has been appointed Chief Development Officer (CDO), starting September 13. He will join the management team and have a key role in the clinical development of the company´s project portfolio.
The appointment of Paul Hargreaves as CDO marks an important step for Spago Nanomedical as the company continues to make progress with its unique project portfolio, with the Tumorad® candidate drug SN201 rapidly advancing towards clinical trials. This is an opportunity to provide potential treatment for advanced cancers of different origins.
Paul Hargreaves is a clinical pharmacologist with almost 30 years experience in clinical development in both the pharmaceutical and large CRO industry. At present, he serves as CDO with smaller Danish biotech companies, before that he held the position as Vice President, Head of Global Clinical Operations at LEO Pharma.
“We are very happy to have Paul joining Spago Nanomedical. His extensive experience from clinical development will become a valuable asset as we are progressing and rapidly coming into clinical phase with Tumorad®,” says CEO Mats Hansen.
”I´m excited to join Spago Nanomedical at a stage where the clinical development of the company´s projects accelerates. By means of Tumorad®, we can create opportunities for treatment of advanced cancers and eventually help patients in a way that is not possible today. I look forward to work with the group and take the company to the next level,” says Paul Hargreaves.
For further information, please contact Mats Hansen CEO Spago Nanomedical AB, +46 46 81188, [email protected].
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, [email protected]
Framtagning av lågtiter blodgrupp 0 helblod: Presentation av resultat vid SABM 2021 (översättning)
Översättning av PM SEP 24, 2021 17:15 CET:Manufacturing of low titer-blood group O whole blood: Presentation of results at the SABM 2021 Annual Meeting Glycorex Transplantation AB (publ.), noterat på NGM Main Regulated Equity, meddelar att Transfusionenheten vid University of R...
Nanexa pausar NEX-18-studien
De måttliga hudreaktioner som uppkommit skiljer sig något från den milda reaktion som normalt uppstår efter administrering av 5-azacitidin. För att klargöra vad detta beror på gör Nanexa tillsammans med klinikerna en utredning inklusive biopsier av den påverkade huden. Utredningen väntas vara klar u...
Nanexa pauses NEX-18 study
The moderate skin reactions that have occured differ slightly from the mild reaction that normally occurs after the administration of 5-azacitidine. To clarify the cause, Nanexa together with the clinics is conducting an investigation including biopsies of the affected skin. The investigation is exp...
Manufacturing of low titer-blood group O whole blood: Presentation of results at the SABM 2021 Annual Meeting
Glycorex Transplantation AB (publ.), listed on NGM Main Regulated Equity, announces thatthe Transfusion unit at the University of Rochester Medical Center presents their experience with the UBP-product for the manufacturing of low titer-blood group O whole blood (LTOWB) attheSociet...